Vaxart Publishes Phase 1 Trial Data Showing Vaccine Efficacy in Breastfeeding Women
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy ?
Vaxart announced the publication in npj Vaccines of data from a double-blind, placebo-controlled Phase 1 trial evaluating a single-dose, oral bivalent vaccine candidate in post-partum, breastfeeding women. Topline safety and immunogenicity results in lactating women were initially reported in April 2024; the newly published study additionally shows vaccine-induced functional norovirus-specific antibodies in breastmilk and serum from vaccinated women, and norovirus-specific IgA in the stool of their breastfed infants. A positive correlation between levels of breast milk IgA and infant stool IgA was observed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
